empagliflozin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
sodium glucose co-transporter inhibitors, phlorizin derivatives 4830 864070-44-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • empagliflozin
  • BI 10773
  • jardiance
Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
  • Molecular weight: 450.91
  • Formula: C23H27ClO7
  • CLOGP: 2.58
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 4
  • TPSA: 108.61
  • ALOGS: -3.61
  • ROTB: 6
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
17.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
S (Water solubility) 0.11 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.566 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 25.823 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 3.673 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.312 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 14.830 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 25.090 % High 1
herg hERG pIC50 4.436 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.528 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.451 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 15.100 % High 1
kinase-safety-class ACVR2B,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK10,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK,ZAP70 17
kinase-selectivity-class MAP2K6 1
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 17.539 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 8.531 High 1
mh-clint Mouse hepatocyte intrinsic clearance 10.375 High 1
mppb Mouse plasma protein binding (% unbound) 10.950 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 20.277 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 19.350 % High 1
rat-kpuu-brain Rat brain Kpuu 0.017 % High 1
rh-clint Rat hepatocyte intrinsic clearance 5.248 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 76.310 % High 1
rppb Rat plasma protein binding (% unbound) 7.740 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 881.049 uM High 1

Approvals:

DateAgencyCompanyOrphan
Aug. 1, 2014 FDA BOEHRINGER INGELHEIM
March 20, 2014 EMA
Dec. 26, 2014 PMDA Nippon Boehringer Ingelheim Co., Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diabetic ketoacidosis 5267.34 12.30 1355 37553 23052 90566487
Euglycaemic diabetic ketoacidosis 3547.26 12.30 760 38148 5441 90584098
Ketoacidosis 2428.43 12.30 547 38361 5048 90584491
Fungal infection 1326.12 12.30 545 38363 42116 90547423
Lactic acidosis 495.35 12.30 294 38614 50169 90539370
Metabolic acidosis 349.72 12.30 245 38663 55431 90534108
Acute kidney injury 312.31 12.30 521 38387 319866 90269673
Glycosylated haemoglobin increased 286.77 12.30 138 38770 15424 90574115
Urinary tract infection 272.72 12.30 478 38430 305154 90284385
Blood ketone body increased 268.14 12.30 55 38853 306 90589233
Blood glucose increased 258.75 12.30 258 38650 94988 90494551
Hypoglycaemia 200.43 12.30 195 38713 69653 90519886
Ketosis 179.14 12.30 46 38862 763 90588776
Dehydration 174.31 12.30 305 38603 194142 90395397
Glomerular filtration rate decreased 166.91 12.30 99 38809 16833 90572706
Necrotising fasciitis 163.96 12.30 62 38846 3818 90585721
Malignant mediastinal neoplasm 145.28 12.30 44 38864 1364 90588175
Cardiac failure 135.46 12.30 199 38709 109297 90480242
Urosepsis 132.21 12.30 93 38815 21139 90568400
Urine ketone body present 130.79 12.30 47 38861 2505 90587034
Vulvovaginal pruritus 130.61 12.30 53 38855 3940 90585599
Emphysematous pyelonephritis 128.39 12.30 30 38878 328 90589211
Vomiting 121.29 12.30 661 38247 787632 89801907
Infusion related reaction 117.65 12.30 19 38889 416761 90172778
Glossodynia 116.78 12.30 5 38903 321774 90267765
Pemphigus 115.65 12.30 6 38902 326858 90262681
Hyperglycaemia 109.65 12.30 122 38786 50848 90538691
Blood glucose abnormal 105.48 12.30 60 38848 9432 90580107
Ketonuria 105.17 12.30 30 38878 751 90588788
Treatment failure 103.20 12.30 7 38901 303921 90285618
Genital infection fungal 103.18 12.30 23 38885 200 90589339
Pericarditis 98.67 12.30 4 38904 270147 90319392
Systemic lupus erythematosus 94.60 12.30 20 38888 361876 90227663
Blood immunoglobulin E increased 93.06 12.30 43 38865 4382 90585157
Hypovolaemia 92.99 12.30 61 38847 12370 90577169
Polyuria 91.95 12.30 56 38852 9984 90579555
Vulvovaginal mycotic infection 89.82 12.30 47 38861 6267 90583272
Hyperkalaemia 89.02 12.30 124 38784 64840 90524699
Acetonaemia 89.01 12.30 22 38886 310 90589229
Synovitis 88.73 12.30 17 38891 329735 90259804
Arthropathy 88.35 12.30 24 38884 366218 90223321
Eosinophilic myocarditis 86.37 12.30 25 38883 660 90588879
Wound 85.04 12.30 14 38894 302966 90286573
Sepsis 84.73 12.30 217 38691 179597 90409942
Contraindicated product administered 83.03 12.30 18 38890 320121 90269418
Pancreatitis 82.15 12.30 124 38784 69702 90519837
Helicobacter infection 80.73 12.30 4 38904 226846 90362693
Swelling 80.02 12.30 40 38868 419018 90170521
COVID-19 79.79 12.30 204 38704 168639 90420900
Therapeutic product effect decreased 79.77 12.30 12 38896 277559 90311980
Drug intolerance 77.84 12.30 48 38860 447543 90141996
Impaired healing 77.75 12.30 6 38902 234193 90355346
Maternal exposure during pregnancy 77.25 12.30 29 38879 360034 90229505
Exposure during pregnancy 76.69 12.30 7 38901 238403 90351136
Prerenal failure 75.85 12.30 30 38878 2085 90587454
Folliculitis 74.70 12.30 3 38905 204350 90385189
Pollakiuria 72.70 12.30 80 38828 32925 90556614
Pyelonephritis fungal 71.69 12.30 17 38891 199 90589340
Acidosis 70.62 12.30 52 38856 12684 90576855
Perinephric abscess 70.24 12.30 18 38890 296 90589243
Irritable bowel syndrome 69.75 12.30 5 38903 207443 90382096
Hyperglycaemic hyperosmolar nonketotic syndrome 69.35 12.30 25 38883 1344 90588195
Stomatitis 66.23 12.30 18 38890 274680 90314859
Drug hypersensitivity 66.14 12.30 61 38847 463548 90125991
Pyelonephritis 65.81 12.30 62 38846 21254 90568285
Hypersensitivity 64.65 12.30 60 38848 454617 90134922
Glucose urine present 62.75 12.30 21 38887 903 90588636
Rheumatoid factor positive 61.15 12.30 3 38905 171647 90417892
Rheumatoid arthritis 60.14 12.30 41 38867 362573 90226966
Diabetic ketosis 59.90 12.30 18 38890 543 90588996
Musculoskeletal stiffness 57.03 12.30 28 38880 296504 90293035
Pruritus genital 56.61 12.30 31 38877 4527 90585012
Nausea 56.50 12.30 725 38183 1109591 89479948
Ischaemic contracture of the left ventricle 56.24 12.30 13 38895 135 90589404
Hypophagia 55.93 12.30 73 38835 35864 90553675
Hepatic enzyme increased 55.66 12.30 44 38864 360692 90228847
Injury 55.62 12.30 9 38899 197340 90392199
Urinary tract candidiasis 54.70 12.30 18 38890 734 90588805
Bronchiectasis 54.23 12.30 57 38851 22273 90567266
Genitourinary tract infection 54.03 12.30 14 38894 241 90589298
C3 glomerulopathy 53.93 12.30 13 38895 164 90589375
Glycosylated haemoglobin abnormal 53.18 12.30 14 38894 257 90589282
Genital infection 52.74 12.30 13 38895 181 90589358
Perineal infection 52.67 12.30 13 38895 182 90589357
Musculoskeletal pain 52.54 12.30 6 38902 171245 90418294
Vesicoureteric reflux 51.41 12.30 14 38894 294 90589245
Candida sepsis 50.85 12.30 21 38887 1632 90587907
Joint swelling 50.14 12.30 87 38821 503213 90086326
Glycosuria 50.13 12.30 20 38888 1422 90588117
Vulvovaginal candidiasis 49.75 12.30 27 38881 3873 90585666
Alopecia 48.94 12.30 86 38822 494985 90094554
Pain 48.93 12.30 241 38667 996100 89593439
Fibromyalgia 48.80 12.30 14 38894 206255 90383284
Mobility decreased 47.72 12.30 24 38884 250710 90338829
Candida infection 46.63 12.30 65 38843 33992 90555547
Urine ketone body 46.60 12.30 11 38897 126 90589413
Blood ketone body 46.53 12.30 10 38898 72 90589467
Toe amputation 46.32 12.30 21 38887 2048 90587491
Weight decreased 46.17 12.30 300 38608 379610 90209929
Diabetes mellitus inadequate control 45.92 12.30 48 38860 18636 90570903
Sinusitis 45.60 12.30 48 38860 343040 90246499
Discomfort 45.49 12.30 31 38877 274304 90315235
Ill-defined disorder 44.76 12.30 12 38896 184879 90404660
Diabetic metabolic decompensation 44.24 12.30 20 38888 1937 90587602
Systemic candida 43.72 12.30 27 38881 4932 90584607
Blister 43.38 12.30 28 38880 254970 90334569
Coagulation test abnormal 42.78 12.30 16 38892 955 90588584
Blood cholesterol increased 42.54 12.30 18 38890 207994 90381545
Urine protein/creatinine ratio increased 42.14 12.30 16 38892 996 90588543
Vulval abscess 42.14 12.30 16 38892 996 90588543
Bursitis 41.96 12.30 4 38904 131650 90457889
Altered state of consciousness 41.42 12.30 59 38849 31473 90558066
Glycosylated haemoglobin decreased 41.12 12.30 14 38894 635 90588904
Cardiac failure chronic 40.51 12.30 27 38881 5619 90583920
Hypernatraemia 40.43 12.30 33 38875 9354 90580185
Anion gap increased 38.41 12.30 19 38889 2251 90587288
Renal impairment 37.56 12.30 115 38793 105306 90484233
Nasopharyngitis 37.31 12.30 74 38834 407030 90182509
Pyelonephritis acute 36.64 12.30 25 38883 5407 90584132
Rhabdomyolysis 36.58 12.30 73 38835 51183 90538356
Starvation ketoacidosis 36.50 12.30 10 38898 215 90589324
Vulvovaginal discomfort 35.32 12.30 19 38889 2678 90586861
Necrotising soft tissue infection 35.26 12.30 10 38898 245 90589294
Diarrhoea 35.23 12.30 582 38326 938608 89650931
Oliguria 34.91 12.30 32 38876 10592 90578947
Vulvovaginitis 34.88 12.30 11 38897 391 90589148
Psoriatic arthropathy 33.77 12.30 29 38879 228306 90361233
Renal abscess 33.67 12.30 14 38894 1107 90588432
Crush syndrome 33.36 12.30 10 38898 299 90589240
Hypertension 33.28 12.30 94 38814 457438 90132101
Product use issue 32.85 12.30 57 38851 329862 90259677
Neutropenia 32.73 12.30 29 38879 224875 90364664
Polycythaemia 32.49 12.30 14 38894 1209 90588330
Joint range of motion decreased 32.46 12.30 9 38899 135634 90453905
Pulmonary fibrosis 32.39 12.30 4 38904 107499 90482040
Pancreatitis acute 32.17 12.30 53 38855 32062 90557477
Blood glucose decreased 31.01 12.30 44 38864 23385 90566154
Diabetic ketoacidotic hyperglycaemic coma 30.89 12.30 7 38901 66 90589473
pH body fluid abnormal 30.08 12.30 7 38901 75 90589464
Blood ketone body present 30.00 12.30 7 38901 76 90589463
Thirst 29.98 12.30 36 38872 16259 90573280
Hypercholesterolaemia 29.81 12.30 4 38904 100888 90488651
Leukopenia 29.73 12.30 4 38904 100706 90488833
Gait inability 29.42 12.30 13 38895 146443 90443096
Vascular stent stenosis 29.28 12.30 11 38897 665 90588874
Failure to suspend medication 29.21 12.30 7 38901 86 90589453
Liver disorder 29.10 12.30 8 38900 121261 90468278
Lung disorder 29.03 12.30 14 38894 149869 90439670
Genital erythema 28.72 12.30 6 38902 37 90589502
Catarrh 28.61 12.30 14 38894 1620 90587919
Genital abscess 28.61 12.30 9 38899 317 90589222
Prescribed overdose 28.53 12.30 4 38904 97621 90491918
Septic shock 28.31 12.30 90 38818 84070 90505469
Diabetic coma 28.28 12.30 11 38897 731 90588808
Sleep disorder 28.26 12.30 26 38882 198004 90391535
Sensorimotor disorder 28.10 12.30 11 38897 744 90588795
Blood lactic acid increased 27.99 12.30 26 38882 8752 90580787
Allergic sinusitis 27.99 12.30 15 38893 2098 90587441
Dysuria 27.97 12.30 56 38852 39345 90550194
Pemphigoid 27.37 12.30 26 38882 9000 90580539
Liver injury 27.31 12.30 20 38888 170547 90418992
Perineal pain 27.13 12.30 10 38898 573 90588966
Impaired quality of life 27.06 12.30 41 38867 23103 90566436
Steroid dependence 26.99 12.30 15 38893 2254 90587285
Cerebral infarction 26.79 12.30 44 38864 26552 90562987
BRASH syndrome 26.76 12.30 14 38894 1865 90587674
Night sweats 26.55 12.30 11 38897 128755 90460784
Glucose urine 26.15 12.30 5 38903 18 90589521
Burns second degree 26.07 12.30 14 38894 1966 90587573
Blood pH abnormal 25.73 12.30 5 38903 20 90589519
Embolic cerebellar infarction 25.73 12.30 5 38903 20 90589519
Genital swelling 25.53 12.30 7 38901 151 90589388
Drug ineffective 25.50 12.30 430 38478 1383868 89205671
Contusion 25.36 12.30 43 38865 251173 90338366
Stoma site ulcer 25.32 12.30 8 38900 286 90589253
Urticaria 25.21 12.30 61 38847 312673 90276866
Pancreatic carcinoma 25.16 12.30 24 38884 8353 90581186
Creatinine renal clearance 24.99 12.30 5 38903 24 90589515
Cardiac amyloidosis 24.74 12.30 11 38897 1025 90588514
Overdose 24.59 12.30 19 38889 157690 90431849
Completed suicide 24.56 12.30 16 38892 145042 90444497
Emphysematous cystitis 24.48 12.30 8 38900 319 90589220
Infection 24.44 12.30 77 38831 362017 90227522
Renal cell carcinoma 24.27 12.30 17 38891 3834 90585705
Genital discomfort 23.99 12.30 6 38902 89 90589450
Hypotension 23.98 12.30 229 38679 325168 90264371
Oxygen saturation increased 23.77 12.30 8 38900 350 90589189
Microalbuminuria 23.77 12.30 9 38899 556 90588983
Wound infection 23.76 12.30 8 38900 106394 90483145
Pancreatitis necrotising 23.66 12.30 14 38894 2367 90587172
Vitamin B12 decreased 23.57 12.30 19 38889 5291 90584248
Genital candidiasis 23.49 12.30 7 38901 205 90589334
Cardiac failure acute 23.01 12.30 27 38881 11902 90577637
Limb amputation 22.80 12.30 5 38903 40 90589499
Red blood cell sedimentation rate increased 22.74 12.30 4 38904 82591 90506948
Female reproductive tract disorder 22.73 12.30 9 38899 627 90588912
Chest wall haematoma 22.66 12.30 7 38901 232 90589307
Synovial disorder 22.59 12.30 15 38893 3103 90586436
Lower respiratory tract infection 22.57 12.30 46 38862 250613 90338926
Neoplasm skin 22.48 12.30 15 38893 3127 90586412
Angina pectoris 22.42 12.30 51 38857 39109 90550430
Type 2 diabetes mellitus 22.21 12.30 33 38875 203211 90386328
Skin sensitisation 21.77 12.30 10 38898 1005 90588534
Myalgia 21.66 12.30 139 38769 174986 90414553
Paraesthesia 21.64 12.30 47 38861 250279 90339260
Full blood count abnormal 21.33 12.30 48 38860 36549 90552990
Blood glucose normal 21.23 12.30 4 38904 13 90589526
Blood creatinine increased 21.17 12.30 93 38815 101293 90488246
Peripheral venous disease 21.17 12.30 5 38903 83916 90505623
Body mass index increased 20.88 12.30 11 38897 1486 90588053
Hypocapnia 20.84 12.30 8 38900 513 90589026
Urinary tract infection enterococcal 20.63 12.30 14 38894 3002 90586537
Morganella infection 20.57 12.30 9 38899 807 90588732
Autoimmune disorder 20.52 12.30 4 38904 76740 90512799
Injection site reaction 20.43 12.30 7 38901 92073 90497466
Respiratory sinus arrhythmia magnitude 20.39 12.30 5 38903 68 90589471
Prostatic specific antigen abnormal 20.39 12.30 5 38903 68 90589471
Urine alcohol test positive 20.26 12.30 3 38905 0 90589539
Drug dispensed to wrong patient 19.87 12.30 7 38901 352 90589187
Therapeutic product effect incomplete 19.74 12.30 33 38875 193863 90395676
Insomnia 19.74 12.30 75 38833 333399 90256140
Hyperventilation 19.68 12.30 19 38889 6709 90582830
Headache 19.63 12.30 257 38651 862489 89727050
Blood insulin decreased 19.54 12.30 4 38904 22 90589517
Acute myocardial infarction 19.49 12.30 45 38863 34845 90554694
Haematuria 19.45 12.30 45 38863 34892 90554647
Eyelid haematoma 19.25 12.30 5 38903 87 90589452
Urine output increased 19.21 12.30 11 38897 1751 90587788
Febrile neutropenia 19.02 12.30 24 38884 158325 90431214
Peripheral swelling 19.00 12.30 102 38806 413004 90176535
Toxicity to various agents 18.86 12.30 62 38846 287784 90301755
Leg amputation 18.78 12.30 12 38896 2325 90587214
N-terminal prohormone brain natriuretic peptide increased 18.49 12.30 13 38895 2949 90586590
Polydipsia 18.49 12.30 15 38893 4216 90585323
Atrial fibrillation 18.37 12.30 109 38799 133502 90456037
Hip arthroplasty 18.34 12.30 5 38903 76203 90513336
Bladder cancer 18.15 12.30 17 38891 5784 90583755
Prescribed underdose 17.90 12.30 5 38903 75014 90514525
Vaginal infection 17.79 12.30 20 38888 8420 90581119
Hypoaesthesia 17.74 12.30 72 38836 314138 90275401
Abdominal discomfort 17.72 12.30 126 38782 477202 90112337
Vulvovaginal swelling 17.57 12.30 8 38900 788 90588751
Coma acidotic 17.53 12.30 5 38903 125 90589414
Haemorrhoidal haemorrhage 17.43 12.30 16 38892 5307 90584232
Adverse event 17.24 12.30 15 38893 117403 90472136
Diabetes mellitus 17.12 12.30 64 38844 64811 90524728
Haematochezia 17.11 12.30 68 38840 70845 90518694
Fungal cystitis 16.97 12.30 3 38905 6 90589533
Condition aggravated 16.81 12.30 169 38739 595376 89994163
Vasoconstriction 16.76 12.30 8 38900 877 90588662
Fatigue 16.75 12.30 373 38535 1153650 89435889
Blood bicarbonate abnormal 16.70 12.30 4 38904 49 90589490
Gastroenteritis 16.66 12.30 38 38870 29191 90560348
Disease progression 16.56 12.30 26 38882 156589 90432950
White blood cell count decreased 16.50 12.30 29 38879 167080 90422459
Anal abscess 16.47 12.30 16 38892 5692 90583847
Hyperparathyroidism secondary 16.37 12.30 10 38898 1791 90587748
Glomerular filtration rate abnormal 16.30 12.30 9 38899 1336 90588203
Migraine 16.25 12.30 36 38872 190356 90399183
Weight increased 16.16 12.30 109 38799 417818 90171721
Therapy non-responder 16.13 12.30 21 38887 136683 90452856
Papilloma 15.98 12.30 6 38902 362 90589177
Eyelid injury 15.95 12.30 5 38903 174 90589365
Hypopnoea 15.85 12.30 14 38894 4417 90585122
Haematocrit increased 15.80 12.30 12 38896 3066 90586473
Pancytopenia 15.76 12.30 17 38891 120246 90469293
Blood pH increased 15.66 12.30 7 38901 660 90588879
Gastrointestinal disorder 15.66 12.30 57 38851 256630 90332909
Blood bicarbonate decreased 15.66 12.30 12 38896 3107 90586432
Anxiety 15.66 12.30 74 38834 309698 90279841
Renal failure 15.59 12.30 103 38805 130904 90458635
Inappropriate schedule of product administration 15.56 12.30 114 38794 149819 90439720
Incorrect product formulation administered 15.56 12.30 5 38903 189 90589350
Blood triglycerides increased 15.56 12.30 24 38884 13737 90575802
Road traffic accident 15.50 12.30 14 38894 107612 90481927
Mucosal inflammation 15.42 12.30 3 38905 57622 90531917
Hypovolaemic shock 15.28 12.30 17 38891 7077 90582462
Polycythaemia vera 15.26 12.30 5 38903 201 90589338
Language disorder 15.09 12.30 11 38897 2641 90586898
Glycosylated haemoglobin 15.02 12.30 4 38904 77 90589462
Lower limb fracture 14.91 12.30 9 38899 85004 90504535
Pyrexia 14.90 12.30 197 38711 660288 89929251
Shock 14.86 12.30 36 38872 28742 90560797
Urinary tract infection fungal 14.86 12.30 7 38901 745 90588794
Right atrial enlargement 14.79 12.30 5 38903 222 90589317
Diabetic foot 14.68 12.30 9 38899 1622 90587917
Blood iron decreased 14.55 12.30 27 38881 17932 90571607
Haemoglobin increased 14.54 12.30 17 38891 7464 90582075
Genital tract inflammation 14.43 12.30 4 38904 90 90589449
Periorbital haematoma 14.36 12.30 7 38901 804 90588735
Arthralgia 14.20 12.30 242 38666 778280 89811259
Blood uric acid increased 14.14 12.30 17 38891 7687 90581852
Abnormal loss of weight 14.10 12.30 16 38892 6807 90582732
Vasculitic ulcer 14.03 12.30 5 38903 260 90589279
Coronary artery bypass 13.95 12.30 10 38898 2339 90587200
Dizziness 13.89 12.30 341 38567 588943 90000596
Ventricular asystole 13.77 12.30 4 38904 107 90589432
Meralgia paraesthetica 13.68 12.30 6 38902 541 90588998
Electrolyte imbalance 13.68 12.30 31 38877 23714 90565825
Kussmaul respiration 13.61 12.30 5 38903 284 90589255
Urethral disorder 13.51 12.30 5 38903 290 90589249
Genital herpes zoster 13.47 12.30 3 38905 26 90589513
Nephrolithiasis 13.43 12.30 49 38859 49036 90540503
Illness 13.35 12.30 70 38838 81899 90507640
Laryngitis 12.85 12.30 3 38905 50750 90538789
Cardiac arrest 12.79 12.30 83 38825 104852 90484687
Cough 12.78 12.30 226 38682 368736 90220803
Dyspepsia 12.76 12.30 43 38865 198117 90391422
Blepharospasm 12.67 12.30 4 38904 55441 90534098
Sciatica 12.56 12.30 15 38893 101367 90488172
Pyuria 12.54 12.30 9 38899 2110 90587429
Parkinsonism 12.49 12.30 22 38886 14043 90575496
Amnesia 12.46 12.30 17 38891 108488 90481051
Perineal abscess 12.42 12.30 5 38903 364 90589175
Genital burning sensation 12.39 12.30 5 38903 366 90589173

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diabetic ketoacidosis 4973.59 12.51 1606 50929 20761 42548039
Euglycaemic diabetic ketoacidosis 3783.08 12.51 960 51575 4700 42564100
Ketoacidosis 2057.52 12.51 587 51948 4765 42564035
Urinary tract infection 432.80 12.51 571 51964 98713 42470087
Fungal infection 376.25 12.51 258 52277 19464 42549336
Metabolic acidosis 332.22 12.51 363 52172 51495 42517305
Glycosylated haemoglobin increased 289.77 12.51 187 52348 12737 42556063
Pollakiuria 280.40 12.51 228 52307 22277 42546523
Lactic acidosis 247.64 12.51 292 52243 44969 42523831
Ketonuria 237.84 12.51 69 52466 595 42568205
Balanoposthitis 220.94 12.51 81 52454 1540 42567260
Blood ketone body increased 220.05 12.51 62 52473 476 42568324
Toe amputation 216.08 12.51 94 52441 2835 42565965
Ketosis 212.65 12.51 68 52467 837 42567963
Urine ketone body present 187.57 12.51 69 52466 1325 42567475
Necrotising fasciitis 171.13 12.51 92 52443 4454 42564346
Hyperglycaemia 169.70 12.51 244 52291 45615 42523185
Acidosis 166.99 12.51 131 52404 12148 42556652
Urosepsis 151.86 12.51 135 52400 14885 42553915
Hypovolaemia 150.74 12.51 120 52415 11365 42557435
Dehydration 133.48 12.51 431 52104 141336 42427464
Acute kidney injury 131.47 12.51 837 51698 366500 42202300
Glomerular filtration rate decreased 130.74 12.51 129 52406 16222 42552578
Weight decreased 124.77 12.51 547 51988 207401 42361399
Blood glucose increased 123 12.51 277 52258 73422 42495378
Polyuria 115.41 12.51 97 52438 9914 42558886
Genital infection fungal 114.69 12.51 31 52504 200 42568600
Pancreatitis 111.33 12.51 195 52340 43073 42525727
Blood glucose abnormal 110.76 12.51 82 52453 6971 42561829
Glycosylated haemoglobin abnormal 101.48 12.51 30 52505 278 42568522
Polycythaemia 99.19 12.51 55 52480 2831 42565969
Diabetes mellitus inadequate control 98.89 12.51 108 52427 15282 42553518
Urine ketone body 97.36 12.51 21 52514 40 42568760
Blood ketone body 96.57 12.51 24 52511 105 42568695
Burns second degree 96.01 12.51 71 52464 6025 42562775
Catarrh 94.91 12.51 70 52465 5916 42562884
Febrile neutropenia 94.34 12.51 56 52479 185647 42383153
Drug ineffective 94.25 12.51 429 52106 629768 41939032
Gangrene 90.54 12.51 64 52471 5062 42563738
Steroid dependence 87.70 12.51 70 52465 6652 42562148
Product monitoring error 84.62 12.51 58 52477 4365 42564435
Neutropenia 84.47 12.51 73 52462 199358 42369442
Parosmia 83.50 12.51 72 52463 7619 42561181
Toxicity to various agents 83.17 12.51 96 52439 229040 42339760
Cardiac failure 82.27 12.51 304 52231 106552 42462248
Gingival pain 81.22 12.51 74 52461 8420 42560380
Hypopnoea 79.97 12.51 71 52464 7811 42560989
Hypoglycaemia 79.47 12.51 206 52329 59648 42509152
Disease progression 77.74 12.51 40 52495 143616 42425184
Anaemia 77.62 12.51 142 52393 280136 42288664
Haemoglobin increased 76.13 12.51 58 52477 5148 42563652
Vomiting 75.95 12.51 613 51922 289110 42279690
Phimosis 74.87 12.51 34 52501 1137 42567663
Glycosuria 72.80 12.51 35 52500 1335 42567465
Systemic lupus erythematosus 71.64 12.51 72 52463 9252 42559548
Drug abuse 70.11 12.51 21 52514 104750 42464050
Haematocrit increased 69.78 12.51 42 52493 2525 42566275
Cardiac failure chronic 68.08 12.51 71 52464 9530 42559270
Thrombocytopenia 64.50 12.51 84 52451 190195 42378605
Anion gap increased 64.11 12.51 37 52498 2057 42566743
Thirst 63.95 12.51 67 52468 9041 42559759
Glucose urine present 63.73 12.51 32 52503 1343 42567457
Hyperkalaemia 63.66 12.51 231 52304 80227 42488573
Pancytopenia 63.37 12.51 33 52502 117710 42451090
Swollen tongue 62.98 12.51 102 52433 21129 42547671
Death 62.59 12.51 334 52201 470851 42097949
Acquired phimosis 62.16 12.51 18 52517 154 42568646
Genital infection 62.02 12.51 14 52521 36 42568764
Dysuria 61.16 12.51 125 52410 30971 42537829
Platelet count decreased 59.53 12.51 50 52485 138531 42430269
Hyperthyroidism 58.50 12.51 80 52455 14261 42554539
Rhinitis 58.47 12.51 73 52462 11904 42556896
Dizziness 58.16 12.51 514 52021 248740 42320060
Alcohol poisoning 57.30 12.51 58 52477 7516 42561284
Cardiac murmur 56.29 12.51 74 52461 12701 42556099
Leriche syndrome 55.33 12.51 15 52520 98 42568702
Prostatitis 55.03 12.51 52 52483 6196 42562604
Medication error 54.57 12.51 124 52411 33030 42535770
Orchitis 53.98 12.51 34 52501 2217 42566583
Pruritus genital 53.81 12.51 36 52499 2603 42566197
Perineal abscess 53.60 12.51 20 52515 400 42568400
Diabetic foot 53.42 12.51 38 52497 3035 42565765
Drug interaction 53.26 12.51 161 52374 266838 42301962
Impaired work ability 53.22 12.51 70 52465 12021 42556779
Genital rash 52.70 12.51 24 52511 808 42567992
Glomerular filtration rate abnormal 52.48 12.51 27 52508 1193 42567607
Balanitis candida 51.91 12.51 16 52519 173 42568627
Starvation ketoacidosis 50.93 12.51 15 52520 137 42568663
Blood ketone body present 50.89 12.51 13 52522 65 42568735
pH body fluid abnormal 49.59 12.51 10 52525 11 42568789
Scrotal abscess 49.46 12.51 22 52513 700 42568100
Frequent bowel movements 48.09 12.51 91 52444 21316 42547484
Malignant neoplasm progression 47.92 12.51 38 52497 108362 42460438
Completed suicide 47.67 12.51 30 52505 96435 42472365
Impaired quality of life 47.45 12.51 72 52463 14105 42554695
BRASH syndrome 47.40 12.51 29 52506 1796 42567004
N-terminal prohormone brain natriuretic peptide increased 47.28 12.51 37 52498 3416 42565384
Diabetic ketosis 46.48 12.51 16 52519 251 42568549
Seizure 46.46 12.51 48 52487 120513 42448287
Leukopenia 46.46 12.51 17 52518 74729 42494071
Hypotension 45.77 12.51 502 52033 257129 42311671
Leg amputation 44.59 12.51 32 52503 2591 42566209
Testicular abscess 43.43 12.51 12 52523 85 42568715
Penile discomfort 43.43 12.51 10 52525 29 42568771
Therapeutic drug monitoring analysis incorrectly performed 43.40 12.51 16 52519 309 42568491
Cystitis 42.87 12.51 62 52473 11636 42557164
Left atrial dilatation 42.44 12.51 30 52505 2372 42566428
Kussmaul respiration 42.37 12.51 12 52523 94 42568706
Insulin C-peptide decreased 42.23 12.51 10 52525 34 42568766
Haemoglobin decreased 41.34 12.51 62 52473 132409 42436391
Peripheral artery bypass 41.24 12.51 11 52524 67 42568733
Cellulitis of male external genital organ 40.69 12.51 11 52524 71 42568729
Amputation 40.53 12.51 20 52515 808 42567992
White blood cell count decreased 40.26 12.51 46 52489 110350 42458450
Scrotal cellulitis 39.68 12.51 11 52524 79 42568721
International normalised ratio increased 39.65 12.51 6 52529 48162 42520638
Pneumonia 39.50 12.51 332 52203 421817 42146983
COVID-19 39.24 12.51 261 52274 115687 42453113
Acetonaemia 39.15 12.51 14 52521 247 42568553
Renal impairment 39.05 12.51 251 52284 109977 42458823
Therapy cessation 38.79 12.51 81 52454 20369 42548431
Palpitations 38.61 12.51 144 52391 50653 42518147
Bronchiectasis 38.51 12.51 75 52460 17944 42550856
Vertigo 38.37 12.51 111 52424 34236 42534564
Pancreatitis acute 38.01 12.51 109 52426 33455 42535345
Emphysematous cystitis 37.99 12.51 14 52521 270 42568530
Spleen ischaemia 37.61 12.51 10 52525 60 42568740
Abdominal discomfort 36.95 12.51 187 52348 75068 42493732
Urinary tract candidiasis 36.27 12.51 16 52519 499 42568301
Myelosuppression 35.80 12.51 4 52531 40457 42528343
Anxiety 35.55 12.51 57 52478 118503 42450297
Anion gap abnormal 35.44 12.51 15 52520 422 42568378
Alanine aminotransferase increased 35.42 12.51 34 52501 88372 42480428
Foetal exposure during pregnancy 34.45 12.51 8 52527 47303 42521497
Ischaemic nephropathy 34.28 12.51 10 52525 88 42568712
Diabetic metabolic decompensation 34.27 12.51 25 52510 2077 42566723
Genital discolouration 34.20 12.51 6 52529 0 42568800
Diabetic coma 34.19 12.51 19 52516 982 42567818
Foot amputation 34.10 12.51 18 52517 839 42567961
Genital discomfort 33.71 12.51 9 52526 55 42568745
Pyelonephritis 33.57 12.51 45 52490 7869 42560931
Neutrophil count decreased 32.33 12.51 19 52516 63396 42505404
Ulnar nerve injury 32.20 12.51 10 52525 111 42568689
Mucosal dryness 32.09 12.51 22 52513 1656 42567144
Penile rash 31.90 12.51 7 52528 15 42568785
Anion gap 31.75 12.51 17 52518 816 42567984
Treatment failure 31.59 12.51 19 52516 62605 42506195
Thrombosis 31.57 12.51 23 52512 68488 42500312
Haematuria 31.50 12.51 148 52387 57651 42511149
Circumcision 30.53 12.51 8 52527 45 42568755
Neuropathy peripheral 30.50 12.51 49 52486 101804 42466996
Abnormal loss of weight 30.31 12.51 34 52501 4953 42563847
Limb amputation 30.29 12.51 9 52526 85 42568715
Migraine 30.21 12.51 84 52451 25330 42543470
Genital candidiasis 29.83 12.51 9 52526 90 42568710
Colitis ulcerative 29.63 12.51 85 52450 26090 42542710
Suicide attempt 29.47 12.51 10 52525 46090 42522710
Mucosal inflammation 29.40 12.51 12 52523 49362 42519438
Aspartate aminotransferase increased 29.40 12.51 31 52504 77132 42491668
Penile erythema 29.34 12.51 11 52524 223 42568577
Accidental overdose 29.22 12.51 89 52446 28241 42540559
Ascites 28.86 12.51 17 52518 56661 42512139
Drug resistance 28.80 12.51 4 52531 34244 42534556
Infusion related reaction 28.56 12.51 20 52515 60786 42508014
Cerebrovascular accident 28.34 12.51 211 52324 96949 42471851
Urinary tract infection fungal 28.34 12.51 14 52521 567 42568233
Genital infection male 28.28 12.51 7 52528 30 42568770
Hyperglycaemic hyperosmolar nonketotic syndrome 28.11 12.51 20 52515 1598 42567202
Cardio-respiratory arrest 27.92 12.51 19 52516 58617 42510183
Overdose 27.60 12.51 55 52480 105209 42463591
Penile discharge 27.17 12.51 8 52527 73 42568727
Cerebral infarction 26.78 12.51 92 52443 31077 42537723
Troponin increased 26.72 12.51 67 52468 18995 42549805
Hypoxia 26.62 12.51 28 52507 69758 42499042
Low density lipoprotein abnormal 26.49 12.51 12 52523 399 42568401
Mitral valve incompetence 26.38 12.51 61 52474 16428 42552372
Polydipsia 26.26 12.51 30 52505 4458 42564342
Ejection fraction decreased 26.25 12.51 73 52462 22014 42546786
Diabetic neuropathy 26.18 12.51 30 52505 4472 42564328
Peripheral arterial occlusive disease 26.17 12.51 37 52498 6801 42561999
Stomatitis 25.76 12.51 15 52520 50314 42518486
Necrotising soft tissue infection 25.53 12.51 9 52526 152 42568648
Tinnitus 25.38 12.51 86 52449 28852 42539948
Bone marrow failure 25.31 12.51 5 52530 33088 42535712
Diabetic foot infection 25.04 12.51 14 52521 732 42568068
Glycosylated haemoglobin 24.98 12.51 6 52529 22 42568778
Pancreatic carcinoma 24.63 12.51 43 52492 9463 42559337
Cytomegalovirus infection 24.46 12.51 5 52530 32301 42536499
Pleural effusion 24.43 12.51 52 52483 97114 42471686
Dysgeusia 24.39 12.51 95 52440 34094 42534706
Epididymitis 24.36 12.51 24 52511 3010 42565790
Skin ulcer 24.16 12.51 78 52457 25523 42543277
Skin pressure mark 23.86 12.51 7 52528 63 42568737
Eczema 23.74 12.51 94 52441 33992 42534808
Respiratory distress 23.57 12.51 11 52524 41809 42526991
Acute myocardial infarction 23.45 12.51 137 52398 58028 42510772
Nightmare 23.42 12.51 76 52459 24936 42543864
Plasma cell myeloma 23.21 12.51 15 52520 47563 42521237
Inappropriate schedule of product administration 22.92 12.51 199 52336 95703 42473097
Intentional overdose 22.77 12.51 18 52517 51438 42517362
Multiple organ dysfunction syndrome 22.71 12.51 54 52481 96981 42471819
Spondylolysis 22.05 12.51 7 52528 84 42568716
Atrial fibrillation 22.03 12.51 266 52269 139327 42429473
Lumbosacral radiculoplexus neuropathy 21.97 12.51 7 52528 85 42568715
Creatinine renal clearance increased 21.96 12.51 11 52524 459 42568341
Perineal cellulitis 21.84 12.51 5 52530 14 42568786
Hypophagia 21.81 12.51 78 52457 26878 42541922
Lymphocyte count decreased 21.69 12.51 4 52531 27805 42540995
Varicella zoster pneumonia 21.27 12.51 9 52526 253 42568547
Gastroenteritis 21.18 12.51 56 52479 16393 42552407
Tinea cruris 20.89 12.51 11 52524 510 42568290
Blood glucose fluctuation 20.87 12.51 27 52508 4560 42564240
Urinary hesitation 20.72 12.51 22 52513 3013 42565787
Pancreatitis necrotising 20.69 12.51 24 52511 3625 42565175
Diabetic ketoacidotic hyperglycaemic coma 20.57 12.51 8 52527 180 42568620
Albumin urine present 20.50 12.51 10 52525 394 42568406
Henoch-Schonlein purpura nephritis 20.48 12.51 5 52530 20 42568780
Urinary incontinence 20.43 12.51 66 52469 21602 42547198
Product use issue 20.20 12.51 40 52495 76711 42492089
Pemphigoid 20.11 12.51 44 52491 11423 42557377
Urinary tract operation 20.03 12.51 4 52531 4 42568796
Adrenal insufficiency 20.03 12.51 60 52475 18864 42549936
Pyrexia 19.90 12.51 354 52181 393688 42175112
Prostatic abscess 19.78 12.51 12 52523 732 42568068
Blood lactic acid decreased 19.62 12.51 6 52529 63 42568737
Measles 19.57 12.51 9 52526 310 42568490
Transaminases increased 19.56 12.51 8 52527 32877 42535923
Glycosylated haemoglobin decreased 19.54 12.51 10 52525 437 42568363
Rash maculo-papular 19.45 12.51 11 52524 37492 42531308
Decreased ventricular preload 19.41 12.51 5 52530 26 42568774
Hepatocellular injury 19.37 12.51 3 52532 23675 42545125
Blood creatinine increased 19.31 12.51 214 52321 109789 42459011
Interstitial lung disease 18.89 12.51 43 52492 78419 42490381
Penile swelling 18.82 12.51 13 52522 990 42567810
Urine output increased 18.47 12.51 15 52520 1461 42567339
Myelodysplastic syndrome 18.34 12.51 3 52532 22742 42546058
Agitation 18.27 12.51 32 52503 64282 42504518
Altered state of consciousness 18.25 12.51 78 52457 29181 42539619
Abnormal behaviour 18.24 12.51 5 52530 26446 42542354
N-terminal prohormone brain natriuretic peptide decreased 18.10 12.51 4 52531 9 42568791
Tubulointerstitial nephritis 18.08 12.51 82 52453 31466 42537334
Respiratory failure 17.94 12.51 89 52446 128043 42440757
Blood lactate dehydrogenase increased 17.85 12.51 5 52530 26076 42542724
Hallucination 17.84 12.51 27 52508 57480 42511320
Urinary tract infection bacterial 17.65 12.51 18 52517 2352 42566448
Oxygen saturation decreased 17.64 12.51 33 52502 64654 42504146
Serotonin syndrome 17.60 12.51 5 52530 25840 42542960
Lower respiratory tract infection 17.51 12.51 15 52520 41191 42527609
Pericardial fibrosis 17.42 12.51 7 52528 172 42568628
Rheumatoid arthritis 17.37 12.51 16 52519 42424 42526376
Fasting 17.35 12.51 5 52530 42 42568758
Glucose urine 17.27 12.51 4 52531 12 42568788
Alcoholic ketoacidosis 17.24 12.51 5 52530 43 42568757
Sepsis 17.22 12.51 343 52192 198991 42369809
Genital infection bacterial 17.10 12.51 3 52532 0 42568800
Drug reaction with eosinophilia and systemic symptoms 17.06 12.51 16 52519 42059 42526741
Hypernatraemia 17.03 12.51 38 52497 9994 42558806
Candida infection 17.03 12.51 62 52473 21548 42547252
Coma acidotic 17.03 12.51 4 52531 13 42568787
Scrotal pain 16.95 12.51 12 52523 951 42567849
Genital tract inflammation 16.94 12.51 5 52530 46 42568754
Pneumocystis jirovecii pneumonia 16.92 12.51 5 52530 25176 42543624
Debridement 16.83 12.51 12 52523 962 42567838
Immune-mediated myositis 16.75 12.51 22 52513 3771 42565029
Insomnia 16.63 12.51 82 52453 118171 42450629
Application site haematoma 16.57 12.51 5 52530 50 42568750
Disseminated intravascular coagulation 16.52 12.51 5 52530 24789 42544011
Stress 16.46 12.51 102 52433 44110 42524690
Encephalopathy 16.43 12.51 16 52519 41317 42527483
Leukocyturia 16.42 12.51 11 52524 797 42568003
Blood creatine increased 16.38 12.51 27 52508 5673 42563127
Off label use 16.35 12.51 633 51902 637702 41931098
Glomerular filtration rate increased 16.35 12.51 11 52524 803 42567997
Drug hypersensitivity 16.34 12.51 65 52470 99324 42469476
Angina pectoris 16.31 12.51 82 52453 32814 42535986
Substance use 16.24 12.51 15 52520 1736 42567064
Non-compaction cardiomyopathy 16.14 12.51 5 52530 55 42568745
Cardiac failure acute 16.14 12.51 45 52490 13588 42555212
Lacunar infarction 16.12 12.51 20 52515 3240 42565560
Skin wrinkling 16.06 12.51 9 52526 473 42568327
Gastrointestinal haemorrhage 16.01 12.51 64 52471 97662 42471138
Drug ineffective for unapproved indication 16.00 12.51 20 52515 46143 42522657
Orchidectomy 15.83 12.51 5 52530 59 42568741
Therapeutic product effect decreased 15.74 12.51 15 52520 39135 42529665
Lipase increased 15.72 12.51 38 52497 10528 42558272
Tumour lysis syndrome 15.71 12.51 4 52531 22227 42546573
Staphylococcal infection 15.63 12.51 14 52521 37629 42531171
Herpes zoster 15.51 12.51 15 52520 38862 42529938
Pterygium 15.42 12.51 6 52529 135 42568665
Haematochezia 15.41 12.51 124 52411 58312 42510488
Urine odour abnormal 15.35 12.51 14 52521 1594 42567206
Colitis 15.30 12.51 21 52514 46551 42522249
Respiratory arrest 15.23 12.51 8 52527 28416 42540384
Illness 15.20 12.51 66 52469 24864 42543936
Chronic kidney disease 15.16 12.51 105 52430 47136 42521664
Scrotal dermatitis 15.02 12.51 3 52532 3 42568797
Haemoptysis 14.98 12.51 21 52514 46146 42522654
Hospitalisation 14.65 12.51 45 52490 74285 42494515
Electrocardiogram abnormal 14.58 12.51 36 52499 10109 42558691
Loss of personal independence in daily activities 14.41 12.51 108 52427 49708 42519092
Electrocardiogram QT prolonged 14.41 12.51 23 52512 47922 42520878
Diabetic nephropathy 14.29 12.51 16 52519 2325 42566475
Intentional product misuse 14.04 12.51 35 52500 61865 42506935
Full blood count decreased 13.96 12.51 4 52531 20556 42548244
Chronic coronary syndrome 13.93 12.51 7 52528 294 42568506
Unresponsive to stimuli 13.88 12.51 11 52524 31392 42537408
Peritonitis 13.86 12.51 3 52532 18630 42550170
Stevens-Johnson syndrome 13.85 12.51 5 52530 22173 42546627
Peripheral artery occlusion 13.84 12.51 14 52521 1812 42566988
Fungal cystitis 13.81 12.51 3 52532 6 42568794
Gait disturbance 13.75 12.51 68 52467 97932 42470868
Tremor 13.75 12.51 67 52468 96862 42471938
Tachypnoea 13.70 12.51 58 52477 21604 42547196
Blood potassium increased 13.62 12.51 52 52483 18484 42550316
Liver function test abnormal 13.51 12.51 12 52523 32379 42536421
Muscle atrophy 13.45 12.51 31 52504 8330 42560470
Genitourinary symptom 13.44 12.51 4 52531 38 42568762
Perineal necrosis 13.35 12.51 4 52531 39 42568761
Haematocrit decreased 13.32 12.51 14 52521 34894 42533906
Wheezing 13.20 12.51 30 52505 54751 42514049
Neutrophil count increased 13.18 12.51 4 52531 19800 42549000
Urine abnormality 13.16 12.51 15 52520 2224 42566576
Drug dependence 13.10 12.51 10 52525 29084 42539716
Limb injury 12.97 12.51 43 52492 14262 42554538
Penile infection 12.96 12.51 5 52530 110 42568690
Clostridium difficile colitis 12.92 12.51 5 52530 21247 42547553
Rhabdomyolysis 12.84 12.51 51 52484 77968 42490832
Incorrect route of product administration 12.79 12.51 7 52528 24298 42544502
Penis disorder 12.76 12.51 12 52523 1421 42567379
Genitourinary tract infection 12.75 12.51 5 52530 115 42568685
Spermatic cord inflammation 12.71 12.51 3 52532 10 42568790
Arthritis 12.62 12.51 92 52443 41973 42526827
Anal abscess 12.51 12.51 29 52506 7821 42560979

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diabetic ketoacidosis 7619.31 11.59 2281 78050 39777 110469191
Euglycaemic diabetic ketoacidosis 6810.16 11.59 1599 78732 10024 110498944
Ketoacidosis 3553.24 11.59 923 79408 9164 110499804
Metabolic acidosis 713.06 11.59 586 79745 99158 110409810
Lactic acidosis 641.96 11.59 535 79796 92276 110416692
Urinary tract infection 503.48 11.59 872 79459 325410 110183558
Acute kidney injury 474.97 11.59 1264 79067 634166 109874802
Fungal infection 461.40 11.59 344 79987 50462 110458506
Glycosylated haemoglobin increased 413.29 11.59 241 80090 23378 110485590
Blood ketone body increased 395.00 11.59 98 80233 790 110508178
Ketosis 346.38 11.59 102 80229 1652 110507316
Dehydration 312.96 11.59 652 79679 278859 110230109
Hyperglycaemia 308.82 11.59 344 79987 84746 110424222
Pollakiuria 307.93 11.59 256 80075 43939 110465029
Ketonuria 290.18 11.59 85 80246 1350 110507618
Blood glucose increased 285.43 11.59 413 79918 132083 110376885
Urine ketone body present 267.81 11.59 102 80229 3744 110505224
Urosepsis 265.79 11.59 202 80129 30473 110478495
Glomerular filtration rate decreased 253.80 11.59 192 80139 28764 110480204
Hypoglycaemia 251.65 11.59 363 79968 115741 110393227
Acidosis 244.41 11.59 170 80161 22361 110486607
Necrotising fasciitis 239.92 11.59 115 80216 7476 110501492
Toe amputation 231.79 11.59 95 80236 4243 110504725
Hypovolaemia 231.52 11.59 162 80169 21512 110487456
Cardiac failure 216.08 11.59 443 79888 187183 110321785
Polyuria 204.59 11.59 139 80192 17599 110491369
Balanoposthitis 194.94 11.59 62 80269 1314 110507654
Hyperkalaemia 182.23 11.59 342 79989 135454 110373514
Blood glucose abnormal 177.66 11.59 113 80218 12803 110496165
Infusion related reaction 163.76 11.59 38 80293 381124 110127844
Catarrh 147.53 11.59 82 80249 7253 110501715
Burns second degree 146.17 11.59 83 80248 7650 110501318
Diabetes mellitus inadequate control 145.06 11.59 141 80190 29634 110479334
Weight decreased 141.26 11.59 693 79638 467364 110041604
Steroid dependence 139.16 11.59 83 80248 8386 110500582
Vomiting 137.95 11.59 1130 79201 909545 109599423
Cardiac failure chronic 137.72 11.59 99 80232 13712 110495256
Glossodynia 132.45 11.59 7 80324 221997 110286971
Pancreatitis 129.74 11.59 239 80092 93294 110415674
Glycosuria 128.38 11.59 54 80277 2576 110506392
Blood ketone body 125.63 11.59 29 80302 165 110508803
Therapeutic product effect decreased 123.13 11.59 16 80315 244300 110264668
Synovitis 122.41 11.59 25 80306 274067 110234901
Genital infection fungal 121.33 11.59 30 80301 238 110508730
Emphysematous pyelonephritis 120.24 11.59 35 80296 543 110508425
Malignant mediastinal neoplasm 119.70 11.59 43 80288 1335 110507633
Stomatitis 117.92 11.59 26 80305 270216 110238752
Hypopnoea 116.75 11.59 83 80248 11297 110497671
Acetonaemia 116.59 11.59 34 80297 531 110508437
Treatment failure 112.55 11.59 31 80300 277203 110231765
Maternal exposure during pregnancy 112.27 11.59 24 80307 254859 110254109
Glucose urine present 111.74 11.59 47 80284 2242 110506726
COVID-19 111.26 11.59 411 79920 244649 110264319
Anion gap increased 111.13 11.59 57 80274 4287 110504681
Polycythaemia 110.79 11.59 52 80279 3223 110505745
Drug intolerance 108.51 11.59 82 80249 406430 110102538
Parosmia 108.04 11.59 84 80247 13096 110495872
Arthropathy 108.00 11.59 37 80294 287485 110221483
Folliculitis 107.76 11.59 3 80328 167650 110341318
Helicobacter infection 107.66 11.59 6 80325 181871 110327097
Rheumatoid arthritis 106.73 11.59 42 80289 299571 110209397
Pemphigus 105.87 11.59 15 80316 214555 110294413
Irritable bowel syndrome 105.32 11.59 3 80328 164212 110344756
Swelling 104.14 11.59 63 80268 350978 110157990
Drug hypersensitivity 102.70 11.59 107 80224 453983 110054985
Bronchiectasis 101.70 11.59 129 80202 36364 110472604
Renal impairment 101.06 11.59 334 79997 188111 110320857
Exposure during pregnancy 100.74 11.59 5 80326 167419 110341549
Pericarditis 99.90 11.59 19 80312 219095 110289873
Glycosylated haemoglobin abnormal 99.32 11.59 29 80302 455 110508513
Gingival pain 99.02 11.59 86 80245 15650 110493318
Sepsis 96.02 11.59 481 79850 326865 110182103
Urine ketone body 93.86 11.59 23 80308 175 110508793
Diabetic ketosis 91.94 11.59 32 80299 904 110508064
Dysuria 87.43 11.59 157 80174 60074 110448894
Pruritus genital 87.07 11.59 56 80275 6466 110502502
Toxicity to various agents 87.06 11.59 134 80197 480421 110028547
Drug ineffective 86.29 11.59 700 79631 1519840 108989128
Thirst 86.08 11.59 92 80239 21615 110487353
Impaired quality of life 85.06 11.59 107 80224 29910 110479058
Urinary tract candidiasis 84.20 11.59 32 80299 1167 110507801
Hypotension 83.92 11.59 659 79672 523190 109985778
Phimosis 83.63 11.59 29 80302 810 110508158
Sinusitis 82.86 11.59 57 80274 296631 110212337
Alcohol poisoning 81.67 11.59 61 80270 8959 110500009
Starvation ketoacidosis 81.67 11.59 23 80308 315 110508653
Joint swelling 81.65 11.59 122 80209 442723 110066245
Alopecia 81.26 11.59 87 80244 364666 110144302
Product monitoring error 80.00 11.59 60 80271 8867 110500101
Pancreatitis acute 79.80 11.59 151 80180 60123 110448845
Hypersensitivity 79.74 11.59 106 80225 403892 110105076
BRASH syndrome 78.67 11.59 43 80288 3680 110505288
Hyperglycaemic hyperosmolar nonketotic syndrome 78.47 11.59 40 80291 2969 110505999
Vulvovaginal pruritus 77.46 11.59 41 80290 3290 110505678
Rhinitis 76.38 11.59 88 80243 22457 110486511
Neutropenia 76.29 11.59 96 80235 374524 110134444
Genital infection 75.28 11.59 20 80311 217 110508751
Hypophagia 73.62 11.59 135 80196 52491 110456477
Fibromyalgia 73.42 11.59 17 80314 170892 110338076
Rheumatoid factor positive 73.06 11.59 6 80325 131634 110377334
Cerebral infarction 72.54 11.59 133 80198 51705 110457263
Haematocrit increased 72.24 11.59 45 80286 4914 110504054
Diabetic foot 72.18 11.59 42 80289 4053 110504915
Cardiac murmur 71.71 11.59 89 80242 24539 110484429
Febrile neutropenia 71.17 11.59 75 80256 316692 110192276
Hyperthyroidism 70.04 11.59 96 80235 29165 110479803
Drug abuse 69.84 11.59 21 80310 177390 110331578
Musculoskeletal pain 69.67 11.59 23 80308 183000 110325968
Completed suicide 68.43 11.59 46 80285 242335 110266633
N-terminal prohormone brain natriuretic peptide increased 68.29 11.59 47 80284 6074 110502894
Atrial fibrillation 67.69 11.59 338 79993 229304 110279664
Nasopharyngitis 67.61 11.59 114 80217 394247 110114721
Pyelonephritis 66.81 11.59 87 80244 25163 110483805
Injury 66.22 11.59 23 80308 177242 110331726
Glomerular filtration rate abnormal 66.02 11.59 33 80298 2350 110506618
Acquired phimosis 65.62 11.59 16 80315 119 110508849
Contraindicated product administered 65.03 11.59 51 80280 248216 110260752
Pyelonephritis fungal 64.55 11.59 19 80312 307 110508661
Orchitis 64.33 11.59 30 80301 1832 110507136
Wound 64.18 11.59 46 80285 234391 110274577
Haemoglobin increased 63.71 11.59 53 80278 9094 110499874
Perinephric abscess 63.64 11.59 20 80311 407 110508561
Prostatitis 63.54 11.59 41 80290 4760 110504208
Emphysematous cystitis 62.89 11.59 22 80309 631 110508337
Product use issue 62.28 11.59 81 80250 311614 110197354
Musculoskeletal stiffness 62.02 11.59 67 80264 279755 110229213
Bursitis 61.97 11.59 10 80321 129908 110379060
Acute myocardial infarction 60.50 11.59 165 80166 83612 110425356
Balanitis candida 60.36 11.59 16 80315 172 110508796
Diabetic coma 59.87 11.59 26 80305 1342 110507626
Scrotal abscess 59.81 11.59 21 80310 609 110508359
Necrotising soft tissue infection 59.65 11.59 20 80311 503 110508465
Perineal abscess 58.29 11.59 22 80309 787 110508181
Leriche syndrome 58.21 11.59 15 80316 143 110508825
Leukopenia 57.87 11.59 18 80313 148773 110360195
Hepatic enzyme increased 57.57 11.59 90 80241 320802 110188166
Altered state of consciousness 56.97 11.59 128 80203 57498 110451470
Disease progression 56.83 11.59 56 80275 243978 110264990
Blister 56.71 11.59 49 80282 227327 110281641
Genitourinary tract infection 56.63 11.59 17 80314 295 110508673
Blood cholesterol increased 56.41 11.59 32 80299 184753 110324215
Impaired work ability 56.30 11.59 82 80249 26337 110482631
Pancytopenia 56.24 11.59 42 80289 209571 110299397
Psoriatic arthropathy 55.99 11.59 37 80294 196724 110312244
Diabetic metabolic decompensation 55.92 11.59 35 80296 3854 110505114
Blood creatinine increased 55.88 11.59 272 80059 182617 110326351
Mobility decreased 55.84 11.59 54 80277 237368 110271600
Anxiety 55.31 11.59 104 80227 344974 110163994
Impaired healing 54.63 11.59 38 80293 196679 110312289
Ill-defined disorder 54.19 11.59 23 80308 156830 110352138
Prerenal failure 53.94 11.59 36 80295 4423 110504545
Blood ketone body present 53.73 11.59 14 80317 140 110508828
Candida infection 53.59 11.59 112 80219 47897 110461071
Penile discomfort 53.13 11.59 10 80321 15 110508953
White blood cell count decreased 53.00 11.59 53 80278 229337 110279631
Lower respiratory tract infection 53.00 11.59 59 80272 243047 110265921
Polydipsia 52.42 11.59 44 80287 7644 110501324
Vulvovaginal mycotic infection 52.37 11.59 38 80293 5339 110503629
Blood immunoglobulin E increased 51.38 11.59 43 80288 7439 110501529
Pain 51.07 11.59 446 79885 954509 109554459
Genital rash 50.80 11.59 23 80308 1312 110507656
Kussmaul respiration 49.99 11.59 17 80314 447 110508521
Diabetic ketoacidotic hyperglycaemic coma 49.77 11.59 15 80316 264 110508704
Vesicoureteric reflux 49.36 11.59 14 80317 197 110508771
Therapy cessation 49.32 11.59 104 80227 44753 110464215
Haematuria 48.89 11.59 152 80179 82853 110426115
Swollen tongue 48.80 11.59 124 80207 60238 110448730
Ischaemic contracture of the left ventricle 48.77 11.59 13 80318 143 110508825
Leg amputation 48.50 11.59 33 80298 4185 110504783
Hypernatraemia 48.05 11.59 62 80269 17771 110491197
Genital candidiasis 47.58 11.59 14 80317 226 110508742
Anion gap abnormal 47.03 11.59 19 80312 817 110508151
Eosinophilic myocarditis 46.61 11.59 25 80306 2060 110506908
Left atrial dilatation 46.12 11.59 30 80301 3530 110505438
Haematochezia 46.03 11.59 186 80145 115338 110393630
Testicular abscess 45.94 11.59 11 80320 75 110508893
Cellulitis of male external genital organ 45.83 11.59 10 80321 42 110508926
Gait inability 45.52 11.59 21 80310 136355 110372613
Scrotal cellulitis 45.45 11.59 11 80320 79 110508889
Pemphigoid 44.69 11.59 63 80268 19644 110489324
Paraesthesia 44.60 11.59 83 80248 276438 110232530
Systemic candida 44.44 11.59 45 80286 9929 110499039
Insulin C-peptide decreased 44.30 11.59 11 80320 89 110508879
Contusion 44.23 11.59 63 80268 233298 110275670
Inappropriate schedule of product administration 44.17 11.59 276 80055 203361 110305607
Nightmare 43.77 11.59 91 80240 38772 110470196
Troponin increased 43.72 11.59 78 80253 29688 110479280
Angina pectoris 43.30 11.59 121 80210 62174 110446794
Ischaemic nephropathy 43.25 11.59 11 80320 99 110508869
Insomnia 43.11 11.59 127 80204 360463 110148505
Spleen ischaemia 42.87 11.59 10 80321 60 110508908
Discomfort 42.67 11.59 56 80275 214651 110294317
Peripheral artery bypass 42.21 11.59 11 80320 110 110508858
Foot amputation 41.55 11.59 19 80312 1109 110507859
Diabetic neuropathy 41.53 11.59 37 80294 6962 110502006
Amputation 41.41 11.59 18 80313 931 110508037
Gangrene 41.21 11.59 55 80276 16286 110492682
Peripheral venous disease 41.20 11.59 6 80325 84111 110424857
Candida sepsis 40.95 11.59 26 80305 2935 110506033
Pyelonephritis acute 40.57 11.59 37 80294 7176 110501792
Liver injury 40.52 11.59 30 80301 150383 110358585
Accidental overdose 40.37 11.59 105 80226 51729 110457239
Thrombocytopenia 40.19 11.59 125 80206 348760 110160208
Glucose urine 40.13 11.59 9 80322 44 110508924
Dizziness 39.75 11.59 720 79611 697473 109811495
Therapeutic drug monitoring analysis incorrectly performed 39.43 11.59 16 80315 696 110508272
Tubulointerstitial nephritis 39.27 11.59 107 80224 54177 110454791
Platelet count decreased 39.11 11.59 67 80264 230376 110278592
Liver disorder 38.80 11.59 28 80303 142215 110366753
Joint range of motion decreased 38.78 11.59 20 80311 121812 110387156
Seizure 38.75 11.59 63 80268 221122 110287846
Vulvovaginal candidiasis 38.49 11.59 26 80305 3259 110505709
Hypertension 38.11 11.59 216 80115 509868 109999100
Mitral valve incompetence 37.48 11.59 78 80253 33251 110475717
Myelosuppression 37.43 11.59 11 80320 94329 110414639
Pancreatic carcinoma 37.42 11.59 50 80281 14822 110494146
Red blood cell sedimentation rate increased 37.40 11.59 6 80325 78296 110430672
Genital discolouration 37.37 11.59 6 80325 0 110508968
Haemoglobin decreased 37.22 11.59 78 80253 248649 110260319
Blood glucose fluctuation 36.64 11.59 36 80295 7662 110501306
Blood pH abnormal 36.58 11.59 8 80323 34 110508934
Pancreatitis necrotising 36.51 11.59 31 80300 5470 110503498
Overdose 36.10 11.59 72 80259 233722 110275246
Injection site reaction 36.05 11.59 10 80321 89060 110419908
Nausea 36.04 11.59 1162 79169 1234528 109274440
Eczema 35.95 11.59 125 80206 72168 110436800
Cerebrovascular accident 35.81 11.59 240 80091 181044 110327924
Dysgeusia 35.67 11.59 122 80209 69863 110439105
Blood glucose decreased 35.52 11.59 71 80260 29417 110479551
Medication error 35.31 11.59 161 80170 105205 110403763
Cardiac failure acute 35.24 11.59 63 80268 24015 110484953
Wound infection 35.19 11.59 13 80318 96452 110412516
Blood lactic acid increased 35.02 11.59 50 80281 15771 110493197
Mucosal inflammation 35 11.59 13 80318 96128 110412840
Mucosal dryness 34.57 11.59 27 80304 4236 110504732
Peripheral arterial occlusive disease 34.46 11.59 38 80293 9242 110499726
Arthralgia 34.12 11.59 382 79949 779250 109729718
Vertigo 33.91 11.59 139 80192 86731 110422237
Lung disorder 33.72 11.59 49 80282 179998 110328970
Memory impairment 33.65 11.59 57 80274 196887 110312081
Pulmonary fibrosis 33.61 11.59 16 80315 102026 110406942
Hypercholesterolaemia 33.55 11.59 12 80319 90825 110418143
Prescribed overdose 33.33 11.59 11 80320 87570 110421398
Perineal infection 33.19 11.59 15 80316 852 110508116
Urinary tract infection fungal 33.15 11.59 17 80314 1278 110507690
Glycosylated haemoglobin decreased 33.11 11.59 15 80316 857 110508111
Headache 33.09 11.59 447 79884 881930 109627038
Urticaria 32.78 11.59 120 80211 318737 110190231
Gastroenteritis 32.71 11.59 81 80250 38719 110470249
Vulval abscess 32.51 11.59 15 80316 894 110508074
Palpitations 32.18 11.59 212 80119 159000 110349968
Gastrointestinal disorder 32.06 11.59 81 80250 241871 110267097
pH body fluid abnormal 31.71 11.59 9 80322 127 110508841
Systemic lupus erythematosus 31.54 11.59 88 80243 254250 110254718
Neutrophil count decreased 31.46 11.59 25 80306 120916 110388052
Genital infection male 31.13 11.59 6 80325 11 110508957
Ejection fraction decreased 31.00 11.59 82 80249 40798 110468170
Genital erythema 30.70 11.59 11 80320 339 110508629
Wheezing 30.41 11.59 90 80241 255140 110253828
Therapy non-responder 30.26 11.59 42 80289 157265 110351703
Urine output increased 30.16 11.59 21 80310 2765 110506203
Vulvovaginitis 30.01 11.59 11 80320 362 110508606
Coagulation test abnormal 29.91 11.59 17 80314 1569 110507399
Penile rash 29.86 11.59 6 80325 15 110508953
Tachypnoea 29.86 11.59 79 80252 39316 110469652
Diabetic foot infection 29.79 11.59 14 80317 870 110508098
Abnormal loss of weight 29.75 11.59 37 80294 10220 110498748
Chronic kidney disease 29.72 11.59 122 80209 76169 110432799
Sciatica 29.66 11.59 15 80316 92384 110416584
International normalised ratio increased 29.52 11.59 13 80318 86759 110422209
Peripheral artery occlusion 29.37 11.59 21 80310 2884 110506084
Tinnitus 28.66 11.59 103 80228 60437 110448531
Night sweats 28.66 11.59 33 80298 133950 110375018
Ulnar nerve injury 28.61 11.59 10 80321 286 110508682
Penile discharge 28.60 11.59 7 80324 53 110508915
Fungal cystitis 28.59 11.59 6 80325 20 110508948
Genital swelling 28.37 11.59 11 80320 424 110508544
Therapeutic product effect incomplete 28.07 11.59 77 80254 223728 110285240
Diabetic nephropathy 27.98 11.59 22 80309 3486 110505482
Left ventricular dysfunction 27.62 11.59 56 80275 23437 110485531
Aspartate aminotransferase increased 27.59 11.59 46 80285 159890 110349078
Anal abscess 27.57 11.59 38 80293 11600 110497368
Obesity 27.56 11.59 25 80306 113326 110395642
Epididymitis 27.54 11.59 19 80312 2465 110506503
Renal abscess 27.53 11.59 16 80315 1540 110507428
Cardiac amyloidosis 27.52 11.59 20 80311 2817 110506151
Blood bicarbonate decreased 27.39 11.59 27 80304 5770 110503198
Debridement 27.21 11.59 17 80314 1866 110507102
Failure to suspend medication 27.18 11.59 11 80320 475 110508493
Inflammation 26.93 11.59 63 80268 193175 110315793
Blepharospasm 26.66 11.59 4 80327 54847 110454121
Product prescribing error 26.61 11.59 90 80241 51241 110457727
Blood urea increased 26.44 11.59 94 80237 54863 110454105
Cytomegalovirus infection 26.39 11.59 4 80327 54440 110454528
Anion gap 26.39 11.59 17 80314 1968 110507000
Coma acidotic 26.32 11.59 8 80323 145 110508823
Language disorder 26.24 11.59 22 80309 3816 110505152
Peripheral swelling 26.06 11.59 179 80152 403855 110105113
Sleep disorder 25.93 11.59 67 80264 198577 110310391
Crush syndrome 25.80 11.59 10 80321 385 110508583
Skin pressure mark 25.33 11.59 7 80324 89 110508879
Hip arthroplasty 25.09 11.59 5 80326 55808 110453160
Genital abscess 25.07 11.59 9 80322 279 110508689
Suicide attempt 24.90 11.59 23 80308 103371 110405597
Penile swelling 24.83 11.59 12 80319 794 110508174
Electrolyte imbalance 24.83 11.59 71 80260 36957 110472011
Penile erythema 24.74 11.59 8 80323 179 110508789
Prostatic abscess 24.72 11.59 11 80320 602 110508366
Arrhythmia 24.57 11.59 108 80223 69467 110439501
Septic shock 24.49 11.59 197 80134 157331 110351637
Epilepsy 24.48 11.59 22 80309 100187 110408781
Ventricular tachycardia 24.46 11.59 86 80245 49923 110459045
Bone marrow failure 24.35 11.59 6 80325 57842 110451126
Stress 24.23 11.59 145 80186 105203 110403765
Frequent bowel movements 23.85 11.59 109 80222 71281 110437687
Lumbosacral radiculoplexus neuropathy 23.62 11.59 7 80324 116 110508852
Alcoholic ketoacidosis 23.40 11.59 6 80325 56 110508912
Tinea cruris 23.35 11.59 10 80321 499 110508469
Blood glucose normal 23.11 11.59 5 80326 20 110508948
Lower limb fracture 23.06 11.59 13 80318 75335 110433633
Osteoporosis 22.68 11.59 18 80313 87134 110421834
Infection 22.60 11.59 162 80169 362038 110146930
Urinary hesitation 22.57 11.59 22 80309 4636 110504332
Albumin urine present 22.56 11.59 11 80320 742 110508226
Embolic cerebellar infarction 22.54 11.59 5 80326 23 110508945
Leukocytosis 22.50 11.59 88 80243 53740 110455228
Limb amputation 22.43 11.59 7 80324 139 110508829
Bladder cancer 22.25 11.59 47 80284 20245 110488723
Intentional product misuse 22.21 11.59 39 80292 132865 110376103
Varicella zoster pneumonia 21.89 11.59 9 80322 405 110508563
Hypoaesthesia 21.88 11.59 136 80195 314087 110194881
Genital discomfort 21.85 11.59 7 80324 152 110508816
Back injury 21.83 11.59 4 80327 47395 110461573
Pyrexia 21.75 11.59 492 79839 897773 109611195
Oliguria 21.37 11.59 44 80287 18613 110490355
Orchidectomy 21.16 11.59 5 80326 32 110508936
Chronic coronary syndrome 21.12 11.59 8 80323 289 110508679
Stoma site ulcer 21.04 11.59 8 80323 292 110508676
Adverse event 20.98 11.59 29 80302 108780 110400188
Colitis ulcerative 20.77 11.59 111 80220 77252 110431716
Perineal necrosis 20.66 11.59 7 80324 182 110508786
Allergic sinusitis 20.64 11.59 14 80317 1767 110507201
Osteoarthritis 20.61 11.59 66 80265 182557 110326411
Malignant neoplasm progression 20.47 11.59 62 80269 174505 110334463
Lacunar infarction 20.39 11.59 24 80307 6262 110502706
Road traffic accident 20.33 11.59 29 80302 107369 110401599
Ischaemic cardiomyopathy 20.26 11.59 27 80304 7984 110500984
Drug resistance 19.89 11.59 8 80323 56366 110452602
Hypovolaemic shock 19.87 11.59 37 80294 14546 110494422
Pyuria 19.74 11.59 16 80315 2647 110506321
Leukocyturia 19.59 11.59 15 80316 2285 110506683
Coronary artery bypass 19.49 11.59 23 80308 6019 110502949
Type 2 diabetes mellitus 19.34 11.59 65 80266 177167 110331801
Spondylolysis 19.23 11.59 7 80324 226 110508742
Pericardial fibrosis 19.08 11.59 7 80324 231 110508737
Immune-mediated myositis 19.05 11.59 23 80308 6163 110502805
Peripheral ischaemia 18.90 11.59 31 80300 11027 110497941
Blood lactic acid decreased 18.86 11.59 9 80322 579 110508389
Perineal cellulitis 18.67 11.59 5 80326 56 110508912
Laryngitis 18.65 11.59 4 80327 42407 110466561
Joint stiffness 18.65 11.59 13 80318 67230 110441738
Sedation 18.63 11.59 14 80317 69669 110439299
Creatinine renal clearance 18.59 11.59 5 80326 57 110508911
Urine albumin/creatinine ratio increased 18.53 11.59 11 80320 1102 110507866
Extremity necrosis 18.50 11.59 18 80313 3784 110505184
Substance use 18.46 11.59 15 80316 2491 110506477
Non-compaction cardiomyopathy 18.44 11.59 5 80326 59 110508909
Onychomycosis 18.29 11.59 3 80328 38528 110470440
Decreased ventricular preload 18.28 11.59 5 80326 61 110508907
Fasting 18.06 11.59 5 80326 64 110508904
Genital tract inflammation 18.01 11.59 6 80325 148 110508820
Sensorimotor disorder 18.00 11.59 11 80320 1161 110507807
Blood bicarbonate abnormal 17.82 11.59 6 80325 153 110508815
Respiratory sinus arrhythmia magnitude 17.79 11.59 5 80326 68 110508900
Blood insulin decreased 17.76 11.59 4 80327 20 110508948
Measles 17.73 11.59 9 80322 662 110508306
Hypocapnia 17.71 11.59 10 80321 912 110508056
Lupus-like syndrome 17.63 11.59 4 80327 40788 110468180
Cardio-respiratory arrest 17.59 11.59 36 80295 115800 110393168
Dry mouth 17.56 11.59 80 80251 199868 110309100
Perineal pain 17.56 11.59 12 80319 1533 110507435
Bronchitis 17.54 11.59 57 80274 156975 110351993
Postprandial hypoglycaemia 17.42 11.59 6 80325 164 110508804
Blood pressure decreased 17.38 11.59 143 80188 114948 110394020
Microalbuminuria 17.36 11.59 11 80320 1238 110507730
Drug ineffective for unapproved indication 17.34 11.59 30 80301 102808 110406160
Acidosis hyperchloraemic 17.27 11.59 12 80319 1574 110507394
Neoplasm progression 17.24 11.59 13 80318 64582 110444386
Application site haematoma 17.15 11.59 5 80326 78 110508890
Muscle spasms 17.06 11.59 125 80206 278032 110230936
Pneumocystis jirovecii pneumonia 16.92 11.59 5 80326 42730 110466238
Starvation 16.74 11.59 10 80321 1013 110507955
Penis disorder 16.68 11.59 10 80321 1020 110507948
Presyncope 16.59 11.59 75 80256 48812 110460156
Chest wall haematoma 16.59 11.59 8 80323 527 110508441
Product quality issue 16.57 11.59 19 80312 77280 110431688
Hyperventilation 16.55 11.59 26 80305 8921 110500047
Nail disorder 16.33 11.59 11 80320 57924 110451044
Left atrial enlargement 16.33 11.59 12 80319 1719 110507249
Gait disturbance 16.13 11.59 127 80204 278081 110230887
Scrotal pain 15.93 11.59 8 80323 575 110508393
Generalised tonic-clonic seizure 15.93 11.59 10 80321 54670 110454298
Troponin I abnormal 15.93 11.59 4 80327 34 110508934
Drug withdrawal syndrome 15.91 11.59 4 80327 38050 110470918
Dyspepsia 15.83 11.59 78 80253 190887 110318081
Circumcision 15.83 11.59 4 80327 35 110508933
Lipase increased 15.76 11.59 39 80292 18633 110490335
N-terminal prohormone brain natriuretic peptide decreased 15.73 11.59 4 80327 36 110508932
Ascites 15.72 11.59 27 80304 92781 110416187
Electrocardiogram abnormal 15.71 11.59 39 80292 18670 110490298
Toxic epidermal necrolysis 15.68 11.59 11 80320 56716 110452252
Perirectal abscess 15.67 11.59 13 80318 2221 110506747
Fatigue 15.67 11.59 723 79608 1215235 109293733
Abortion spontaneous 15.56 11.59 3 80328 34279 110474689
Orthopaedic procedure 15.43 11.59 6 80325 233 110508735
Blood creatine increased 15.41 11.59 29 80302 11492 110497476
Foot deformity 15.36 11.59 8 80323 48472 110460496
Posterior reversible encephalopathy syndrome 15.29 11.59 3 80328 33858 110475110
Neoplasm skin 15.28 11.59 15 80316 3189 110505779
Alanine aminotransferase increased 15.27 11.59 75 80256 183698 110325270
Urinary tract infection enterococcal 15.22 11.59 16 80315 3686 110505282
Gastrooesophageal reflux disease 15.22 11.59 73 80258 179903 110329065
Hyperlactacidaemia 15.22 11.59 24 80307 8262 110500706
Eyelid haematoma 15.17 11.59 5 80326 119 110508849
Adrenal insufficiency 15.12 11.59 66 80265 42324 110466644
Amnesia 14.98 11.59 34 80297 105374 110403594
Neck pain 14.96 11.59 43 80288 123087 110385881
Intensive care 14.96 11.59 13 80318 2366 110506602
Post procedural complication 14.94 11.59 48 80283 26610 110482358
Multiple sclerosis relapse 14.90 11.59 9 80322 50231 110458737
Micturition urgency 14.90 11.59 39 80292 19281 110489687
Lymphocyte count decreased 14.67 11.59 12 80319 57231 110451737
Escherichia pyelonephritis 14.66 11.59 9 80322 958 110508010
Anaemia 14.56 11.59 295 80036 546791 109962177
Urine alcohol test positive 14.54 11.59 4 80327 50 110508918
Spermatic cord inflammation 14.53 11.59 3 80328 9 110508959
Stevens-Johnson syndrome 14.48 11.59 8 80323 46893 110462075
Unevaluable event 14.47 11.59 13 80318 59214 110449754
Penile abscess 14.37 11.59 5 80326 141 110508827
Urinary tract infection bacterial 14.31 11.59 23 80308 8044 110500924
Encephalopathy 14.27 11.59 23 80308 81032 110427936
Blood triglycerides increased 14.26 11.59 44 80287 23882 110485086
Synovial disorder 14.19 11.59 14 80317 2993 110505975
Vulvovaginal discomfort 14.16 11.59 12 80319 2112 110506856
Agitation 14.09 11.59 39 80292 113012 110395956
Blood thyroid stimulating hormone increased 14.08 11.59 29 80302 12272 110496696
Morganella infection 14.01 11.59 10 80321 1369 110507599
Prescribed underdose 13.99 11.59 16 80315 65158 110443810
Genital pain 13.88 11.59 10 80321 1390 110507578
Oxygen saturation increased 13.86 11.59 8 80323 760 110508208
Ear pain 13.84 11.59 11 80320 53215 110455753
Polycythaemia vera 13.75 11.59 7 80324 518 110508450
Left ventricular hypertrophy 13.74 11.59 30 80301 13214 110495754
Limb injury 13.73 11.59 59 80272 37577 110471391
Vitamin B12 decreased 13.73 11.59 18 80313 5239 110503729
Skin ulcer 13.62 11.59 86 80245 63559 110445409
Vasoconstriction 13.52 11.59 9 80322 1101 110507867
Intentional overdose 13.52 11.59 50 80281 132451 110376517
Adenocarcinoma pancreas 13.50 11.59 12 80319 2251 110506717
Skin sensitisation 13.45 11.59 9 80322 1110 110507858
Prostatomegaly 13.44 11.59 16 80315 4226 110504742
Penile infection 13.40 11.59 4 80327 68 110508900
Low density lipoprotein abnormal 13.27 11.59 7 80324 558 110508410
Hydronephrosis 13.25 11.59 39 80292 20626 110488342
Urinary incontinence 13.24 11.59 70 80261 48517 110460451
Eyelid injury 13.14 11.59 5 80326 183 110508785
Hypoxia 13.13 11.59 49 80282 129466 110379502
Upper respiratory tract infection 13.11 11.59 50 80281 131278 110377690
Drug-disease interaction 13.03 11.59 11 80320 1925 110507043
Venous pressure jugular 13.01 11.59 3 80328 17 110508951
Urinary retention 13.01 11.59 91 80240 69592 110439376
Penile pain 12.99 11.59 9 80322 1175 110507793
Ear infection 12.83 11.59 16 80315 62716 110446252
Nocturia 12.80 11.59 34 80297 16956 110492012
Blood calcium decreased 12.79 11.59 5 80326 35840 110473128
Bronchopulmonary aspergillosis 12.76 11.59 3 80328 29860 110479108
Renal cell carcinoma 12.72 11.59 21 80310 7509 110501459
Nephrogenic diabetes insipidus 12.70 11.59 12 80319 2433 110506535
Meralgia paraesthetica 12.69 11.59 7 80324 610 110508358
Neutrophilia 12.59 11.59 25 80306 10304 110498664
Ejection fraction abnormal 12.56 11.59 14 80317 3446 110505522
Hepatocellular injury 12.51 11.59 11 80320 50631 110458337
Fluid intake reduced 12.51 11.59 20 80311 6966 110502002
Oedematous pancreatitis 12.39 11.59 10 80321 1644 110507324
Therapy interrupted 12.38 11.59 70 80261 49752 110459216
Herpes zoster 12.34 11.59 39 80292 108340 110400628
Genital burning sensation 12.33 11.59 6 80325 403 110508565
Physical deconditioning 12.31 11.59 14 80317 3523 110505445
Poisoning 12.29 11.59 3 80328 29102 110479866
Systemic infection 12.26 11.59 24 80307 9795 110499173
Diabetes mellitus management 12.22 11.59 3 80328 23 110508945
Serotonin syndrome 12.19 11.59 15 80316 59138 110449830
Panic attack 12.18 11.59 3 80328 28937 110480031
Infarction 12.18 11.59 17 80314 5252 110503716
Pneumonia 12.15 11.59 517 79814 876197 109632771
Incorrect product formulation administered 12.00 11.59 5 80326 233 110508735
Insulin resistance 11.98 11.59 10 80321 1724 110507244
Status epilepticus 11.95 11.59 4 80327 31567 110477401
Haemophagocytic lymphohistiocytosis 11.94 11.59 4 80327 31555 110477413
Myocardial infarction 11.93 11.59 201 80130 191882 110317086
Cardiac ventricular thrombosis 11.88 11.59 13 80318 3134 110505834
Atrial pressure increased 11.88 11.59 4 80327 102 110508866
Ventricular internal diameter abnormal 11.82 11.59 5 80326 242 110508726
Dizziness postural 11.79 11.59 30 80301 14579 110494389
Scrotal ulcer 11.79 11.59 6 80325 444 110508524
Periorbital haematoma 11.69 11.59 8 80323 1024 110507944

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BD19 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD20 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD27 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BK03 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
MeSH PA D000077203 Sodium-Glucose Transporter 2 Inhibitors
MeSH PA D007004 Hypoglycemic Agents
FDA MoA N0000187058 Sodium-Glucose Transporter 2 Inhibitors
FDA EPC N0000187059 Sodium-Glucose Cotransporter 2 Inhibitor
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:50864 insulin-sensitizing drug
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:73273 sodium-glucose transport protein subtype 2 inhibitor
CHEBI has role CHEBI:76916 hyperglycemic agent
CHEBI has role CHEBI:231911 renoprotective agent

Related Drugs by ATC class:

A10BD Combinations of oral blood glucose lowering drugs 19 drugs
acarbosealogliptincanagliflozindapagliflozinertugliflozinevogliptingemigliptinglimepiridelinagliptinlobeglitazonemetforminphenformin show all 19 →
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors 7 drugs
bexagliflozincanagliflozindapagliflozinertugliflozinipragliflozinluseogliflozinsotagliflozin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Chronic heart failure indication 48447003
Cardiovascular event reduce risk 405617006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.62 acidic
pKa2 13.26 acidic
pKa3 13.7 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12527810 April 22, 2033 USE OF EMPAGLIFLOZIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PEDIATRIC PATIENTS AGED 10 YEARS TO 17 YEARS WITH TYPE 2 DIABETES MELLITUS
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12527810 April 22, 2033 USE OF EMPAGLIFLOZIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PEDIATRIC PATIENTS AGED 10 YEARS TO 17 YEARS WITH TYPE 2 DIABETES MELLITUS
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12527810 April 22, 2033 USE OF EMPAGLIFLOZIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PEDIATRIC PATIENTS AGED 10 YEARS TO 17 YEARS WITH TYPE 2 DIABETES MELLITUS
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12527810 April 22, 2033 USE OF EMPAGLIFLOZIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PEDIATRIC PATIENTS AGED 10 YEARS TO 17 YEARS WITH TYPE 2 DIABETES MELLITUS
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12527810 April 22, 2033 USE OF EMPAGLIFLOZIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PEDIATRIC PATIENTS AGED 10 YEARS TO 17 YEARS WITH TYPE 2 DIABETES MELLITUS
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12527810 April 22, 2033 USE OF EMPAGLIFLOZIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PEDIATRIC PATIENTS AGED 10 YEARS TO 17 YEARS WITH TYPE 2 DIABETES MELLITUS
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 11813275 April 3, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 11813275 April 3, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION IN PATIENTS WITH HEART FAILURE BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12263153 April 3, 2034 USE OF EMPAGLIFLOZIN TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12263153 April 3, 2034 USE OF EMPAGLIFLOZIN TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11813275 April 3, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11813275 April 3, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11813275 April 3, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11813275 April 3, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND HEART FAILURE BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH PLUS HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS, HEART FAILURE AND REDUCED EJECTION FRACTION BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 9949997 May 17, 2034 METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 9949997 May 17, 2034 METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL Sept. 21, 2026 USE OF EMPAGLIFLOZIN TO REDUCE THE RISK OF SUSTAINED DECLINE IN EGFR, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
10MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
25MG JARDIANCE BOEHRINGER INGELHEIM N204629 Aug. 1, 2014 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium/glucose cotransporter 2 Transporter INHIBITOR Kd 7.24 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Sodium/glucose cotransporter 4 Transporter IC50 4.96 SCIENTIFIC LITERATURE
Sodium/glucose cotransporter 5 Transporter IC50 5.96 SCIENTIFIC LITERATURE
Sodium/glucose cotransporter 1 Transporter IC50 5.08 SCIENTIFIC LITERATURE
Sodium/myo-inositol cotransporter 2 Transporter IC50 5.70 SCIENTIFIC LITERATURE

External reference:

IDSource
HDC1R2M35U UNII
D10459 KEGG_DRUG
4033569 VUID
N0000190927 NUI
4033569 VANDF
C3490348 UMLSCUI
CHEBI:82720 CHEBI
7R3 PDB_CHEM_ID
CHEMBL2107830 ChEMBL_ID
11949646 PUBCHEM_CID
DB09038 DRUGBANK_ID
9398 INN_ID
C570240 MESH_SUPPLEMENTAL_RECORD_UI
4754 IUPHAR_LIGAND_ID
1545653 RXNORM
227183 MMSL
30461 MMSL
d08275 MMSL
015572 NDDF
703894008 SNOMEDCT_US
703895009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 0597-0152 TABLET, FILM COATED 10 mg ORAL NDA 32 sections
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 0597-0152 TABLET, FILM COATED 10 mg ORAL NDA 32 sections
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 0597-0153 TABLET, FILM COATED 25 mg ORAL NDA 32 sections
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 0597-0153 TABLET, FILM COATED 25 mg ORAL NDA 32 sections
Synjardy HUMAN PRESCRIPTION DRUG LABEL 2 0597-0159 TABLET 5 mg ORAL NDA 34 sections
Synjardy HUMAN PRESCRIPTION DRUG LABEL 2 0597-0159 TABLET 5 mg ORAL NDA 34 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0164 TABLET, FILM COATED 25 mg ORAL NDA 32 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0164 TABLET, FILM COATED 25 mg ORAL NDA 32 sections
Synjardy HUMAN PRESCRIPTION DRUG LABEL 2 0597-0168 TABLET 12.50 mg ORAL NDA 34 sections
Synjardy HUMAN PRESCRIPTION DRUG LABEL 2 0597-0168 TABLET 12.50 mg ORAL NDA 34 sections
Synjardy HUMAN PRESCRIPTION DRUG LABEL 2 0597-0175 TABLET 5 mg ORAL NDA 34 sections
Synjardy HUMAN PRESCRIPTION DRUG LABEL 2 0597-0175 TABLET 5 mg ORAL NDA 34 sections
Synjardy HUMAN PRESCRIPTION DRUG LABEL 2 0597-0180 TABLET 12.50 mg ORAL NDA 34 sections
Synjardy HUMAN PRESCRIPTION DRUG LABEL 2 0597-0180 TABLET 12.50 mg ORAL NDA 34 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0182 TABLET, FILM COATED 10 mg ORAL NDA 32 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0182 TABLET, FILM COATED 10 mg ORAL NDA 32 sections
SynjardyXR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0280 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 34 sections
SynjardyXR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0280 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 34 sections
SynjardyXR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0290 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
SynjardyXR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0290 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
SynjardyXR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0295 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 34 sections
SynjardyXR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0295 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 34 sections
SynjardyXR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0300 TABLET, EXTENDED RELEASE 12.50 mg ORAL NDA 34 sections
SynjardyXR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0300 TABLET, EXTENDED RELEASE 12.50 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0380 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0380 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0385 TABLET, EXTENDED RELEASE 12.50 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0385 TABLET, EXTENDED RELEASE 12.50 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0390 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0390 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 34 sections